NEW YORK (GenomeWeb) – Agendia said Tuesday that updated guidelines from the European Group on Tumor Markers named the firm's MammaPrint 70-gene signature test "as the first and currently the only multigene test of its kind deemed to have level 1A evidence for its clinical use."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.